Mar 24, 2022, 2:41 PM
(From TIME) Moderna’s two-dose COVID vaccine was about 44% effective at preventing infection from omicron in children 6 months to under 2 years old and about 38% effective for children 2- to 5-years-old, according to data released by the company. The results are part of the company’s KidCOVE study and will be submitted to the Food and Drug Administration (FDA) for emergency use authorization in this youngest, and last group of children to be eligible for COVID-19 vaccination. Moderna is also asking the FDA to authorize two doses of its mRNA vaccine in children six to 12 years old, based on data provided to the agency the shots are safe and effective in that age group.
More from TIME
Listen to the latest episode of the Net Assets podcast.
